vs
Church & Dwight（CHD）与莫德纳（MRNA）财务数据对比。点击上方公司名可切换其他公司
Church & Dwight的季度营收约是莫德纳的1.6倍（$1.6B vs $1.0B），Church & Dwight净利率更高（8.7% vs -19.7%，领先28.4%），Church & Dwight同比增速更快（3.9% vs -45.4%），过去两年Church & Dwight的营收复合增速更高（4.6% vs -45.0%）
Church & Dwight是美国知名消费品企业，成立于1847年，总部位于新泽西州尤因。公司主营个人护理、家居用品及特色产品，旗下拥有Arm & Hammer、Trojan、OxiClean等知名品牌，2022年全年营收达54亿美元。
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
CHD vs MRNA — 直观对比
营收规模更大
CHD
是对方的1.6倍
$1.0B
营收增速更快
CHD
高出49.4%
-45.4%
净利率更高
CHD
高出28.4%
-19.7%
两年增速更快
CHD
近两年复合增速
-45.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $1.0B |
| 净利润 | $143.5M | $-200.0M |
| 毛利率 | 45.8% | 79.6% |
| 营业利润率 | 16.2% | -25.6% |
| 净利率 | 8.7% | -19.7% |
| 营收同比 | 3.9% | -45.4% |
| 净利润同比 | -24.2% | -1638.5% |
| 每股收益（稀释后） | $0.60 | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHDMRNA
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | $1.0B | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.6B | $966.0M | ||
| Q3 24 | $1.5B | $1.9B | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
净利润CHDMRNA
| Q4 25 | $143.5M | — | ||
| Q3 25 | $182.2M | $-200.0M | ||
| Q2 25 | $191.0M | — | ||
| Q1 25 | $220.1M | — | ||
| Q4 24 | $189.2M | $-1.1B | ||
| Q3 24 | $-75.1M | $13.0M | ||
| Q2 24 | $243.5M | — | ||
| Q1 24 | $227.7M | — |
毛利率CHDMRNA
| Q4 25 | 45.8% | — | ||
| Q3 25 | 45.1% | 79.6% | ||
| Q2 25 | 43.0% | — | ||
| Q1 25 | 45.0% | — | ||
| Q4 24 | 44.7% | 23.5% | ||
| Q3 24 | 45.2% | 72.4% | ||
| Q2 24 | 47.1% | — | ||
| Q1 24 | 45.7% | — |
营业利润率CHDMRNA
| Q4 25 | 16.2% | — | ||
| Q3 25 | 16.1% | -25.6% | ||
| Q2 25 | 17.4% | — | ||
| Q1 25 | 20.1% | — | ||
| Q4 24 | 16.2% | -129.0% | ||
| Q3 24 | -6.1% | -3.8% | ||
| Q2 24 | 22.3% | — | ||
| Q1 24 | 20.3% | — |
净利率CHDMRNA
| Q4 25 | 8.7% | — | ||
| Q3 25 | 11.5% | -19.7% | ||
| Q2 25 | 12.7% | — | ||
| Q1 25 | 15.0% | — | ||
| Q4 24 | 12.0% | -115.9% | ||
| Q3 24 | -5.0% | 0.7% | ||
| Q2 24 | 16.1% | — | ||
| Q1 24 | 15.1% | — |
每股收益（稀释后）CHDMRNA
| Q4 25 | $0.60 | — | ||
| Q3 25 | $0.75 | $-0.51 | ||
| Q2 25 | $0.78 | — | ||
| Q1 25 | $0.89 | — | ||
| Q4 24 | $0.76 | $-2.91 | ||
| Q3 24 | $-0.31 | $0.03 | ||
| Q2 24 | $0.99 | — | ||
| Q1 24 | $0.93 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $409.0M | $1.1B |
| 总债务越低越好 | $2.2B | — |
| 股东权益账面价值 | $4.0B | $9.3B |
| 总资产 | $8.9B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.55× | — |
8季度趋势，按日历期对齐
现金及短期投资CHDMRNA
| Q4 25 | $409.0M | — | ||
| Q3 25 | $305.3M | $1.1B | ||
| Q2 25 | $923.2M | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $964.1M | $1.9B | ||
| Q3 24 | $752.1M | $1.6B | ||
| Q2 24 | $491.7M | — | ||
| Q1 24 | $349.7M | — |
总债务CHDMRNA
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — |
股东权益CHDMRNA
| Q4 25 | $4.0B | — | ||
| Q3 25 | $4.2B | $9.3B | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $4.6B | — | ||
| Q4 24 | $4.4B | $10.9B | ||
| Q3 24 | $4.2B | $11.9B | ||
| Q2 24 | $4.3B | — | ||
| Q1 24 | $4.1B | — |
总资产CHDMRNA
| Q4 25 | $8.9B | — | ||
| Q3 25 | $9.1B | $12.1B | ||
| Q2 25 | $8.8B | — | ||
| Q1 25 | $9.0B | — | ||
| Q4 24 | $8.9B | $14.1B | ||
| Q3 24 | $8.7B | $15.8B | ||
| Q2 24 | $8.8B | — | ||
| Q1 24 | $8.6B | — |
负债/权益比CHDMRNA
| Q4 25 | 0.55× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.53× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.54× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-847.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-880.0M |
| 自由现金流率自由现金流/营收 | — | -86.6% |
| 资本支出强度资本支出/营收 | 3.4% | 3.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.9B |
8季度趋势，按日历期对齐
经营现金流CHDMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | $-847.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $292.3M | $825.0M | ||
| Q3 24 | $364.0M | $-1.6B | ||
| Q2 24 | $236.9M | — | ||
| Q1 24 | $263.0M | — |
自由现金流CHDMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | $-880.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $237.7M | $303.0M | ||
| Q3 24 | $315.4M | $-1.7B | ||
| Q2 24 | $206.6M | — | ||
| Q1 24 | $216.7M | — |
自由现金流率CHDMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | -86.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 15.0% | 31.4% | ||
| Q3 24 | 20.9% | -92.2% | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 14.4% | — |
资本支出强度CHDMRNA
| Q4 25 | 3.4% | — | ||
| Q3 25 | 1.8% | 3.2% | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 3.5% | 54.0% | ||
| Q3 24 | 3.2% | 8.1% | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 3.1% | — |
现金转化率CHDMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.54× | — | ||
| Q3 24 | — | -120.46× | ||
| Q2 24 | 0.97× | — | ||
| Q1 24 | 1.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHD
| Household Products | $645.3M | 39% |
| Personal Care Products | $625.9M | 38% |
| Consumer International | $299.8M | 18% |
| Specialty Products Division | $73.2M | 4% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
